Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05075824 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)
A Phase 2 study of Sickle Cell Disease, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT05075824: Active Phase 2 study of Sickle Cell Disease, sponsored by Hoffmann-La Roche.
NCT05075824 is a Phase 2 study of Sickle Cell Disease that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 90 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05075824, a Phase 2 study of Sickle Cell Disease, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to evaluate the efficacy, safety and pharmacokinetics of crovalimab compared with placebo as adjunct therapy in the prevention of VOEs in participants with SCD.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Crovalimab
Study Locations (20)
Other
- HEMORIO - Rio de Janeiro
- Hospital Samaritano - São Paulo
- CHU Henri Mondor - Créteil
- International Cancer Institute (ICI) - Eldoret
- Gertrude's Children Hospital - Nairobi
- Hopital Nini - Tripoli
- Amsterdam UMC Location VUMC - Amsterdam
- Charlotte Maxeke Johannesburg Hospital - Johannesburg
São Paulo
- UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu - Botucatu
- Hospital das Clínicas Faculdades Médicas de Ribeirão Preto - Ribeirão Preto
- Hospital de Base de Sao Jose do Rio Preto - São José do Rio Preto
- Beneficencia Portuguesa de Sao Paulo - São Paulo
Michigan
- Children's Hospital of Michigan - Detroit
Mississippi
- Mississippi Center for Advanced Medicine - Madison
New York
- Icahn School of Medicine at Mount Sinai - New York
North Carolina
- East Carolina University - Greenville
Estado de Bahia
- Hospital Sao Rafael - HSR - Salvador
Rio Grande do Sul
- Hospital das Clinicas - UFRGS - Porto Alegre
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 2 |
What the registry record for NCT05075824 still lists
NCT05075824 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05075824 names 20 study sites across 10 states, led by Other, São Paulo, Michigan.
Frequently Asked Questions
What is clinical trial NCT05075824 about?
NCT05075824 is a clinical study titled "A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)". This study is designed to evaluate the efficacy, safety and pharmacokinetics of crovalimab compared with placebo as adjunct therapy in the prevention of VOEs in participants with SCD.
What is the current status of trial NCT05075824?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2022-03-09. Estimated completion is 2026-03-31.
What conditions does trial NCT05075824 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT05075824?
The interventions under investigation include: Placebo (DRUG), Crovalimab (DRUG).
Who is sponsoring clinical trial NCT05075824?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05075824 being conducted?
This trial has 20 study locations across Michigan, Mississippi, New York, North Carolina, Estado de Bahia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05075824's enrollment target sits among peer trials
90 71st of 213 higher than 141 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI